Lifecore Biomedical, Inc. De (LFCR) Current Deferred Revenue (2011 - 2024)

Lifecore Biomedical's Current Deferred Revenue history runs 14 years deep, the most recent figure standing at $9.0 million for Q4 2024.

• In Q4 2024, Current Deferred Revenue rose 4.73% year-over-year to $9.0 million; the TTM figure through Nov 2024 stood at $9.0 million (up 4.73% YoY), while the FY2024 annual figure was $10.6 million, up 51.28% from the prior year.
• Current Deferred Revenue was $9.0 million for Q4 2024 at Lifecore Biomedical, down from $9.3 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $10.6 million in Q2 2024 to a low of $287000.0 in Q2 2021.
• Historically, Current Deferred Revenue has averaged $3.6 million across 5 years, with a median of $1.1 million in 2021.
• The sharpest annual moves came in 2020 and 2023: Current Deferred Revenue tumbled 51.94% in 2020, then soared 1150.81% in 2023.
• A 5-year view of Current Deferred Revenue shows it stood at $297000.0 in 2020, then jumped by 225.59% to $967000.0 in 2021, then decreased by 24.41% to $731000.0 in 2022, then jumped by 1076.47% to $8.6 million in 2023, then grew by 4.73% to $9.0 million in 2024.
• The last three Current Deferred Revenue figures came in at $9.0 million (Q4 2024), $9.3 million (Q3 2024), and $10.6 million (Q2 2024), per Business Quant data.